Skip to main content
INMB logo

INMB · Inmune Bio, Inc.

Track INMB — free
$2.17 +0.09 (+4.33%) At close · Aug 14
Market Cap
$60.23M
Shares
27.75M

Inmune Bio, Inc. Earnings Call Transcripts

Every quarterly earnings call for Inmune Bio, Inc. (INMB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q1
2026-03-31
Inmune Bio, Inc. Q1 FY2026 Earnings Call
Positive tone CORDStrom regulatory filings and MAA submission RDEB program and branding XPro program and MINDFuL study
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Inmune Bio, Inc. Q4 FY2025 Earnings Call
Positive tone CORDStrom RDEB regulatory progress XPro Alzheimer's program INKmune prostate cancer program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Inmune Bio, Inc. Q3 FY2025 Earnings Call
Confident tone CORDStrom RDEB regulatory progress Itch reduction / systemic benefit in RDEB INKmune prostate cancer Phase II
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Inmune Bio, Inc. Q2 FY2025 Earnings Call
Positive tone XPro Phase II MINDFuL trial in Alzheimer's CORDStrom for RDEB regulatory submissions Strategic partnership exploration
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Inmune Bio, Inc. Q1 FY2025 Earnings Call
Confident tone CORDstrom / RDEB program XPro market opportunity INKmune prostate cancer program
Revenue
$50,000
▲ 257.1% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inmune Bio, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Inmune Bio, Inc. Q3 FY2024 Earnings Call
Confident tone XPro ADO2 Phase II Alzheimer’s trial enrollment complete Ease of delivery / outpatient administration Treatment-resistant depression Phase II program
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-02
Inmune Bio, Inc. Q2 FY2024 Earnings Call
Confident tone INKmune NK cell oncology program XPro Phase II Alzheimer's trial (AD02) Treatment-resistant depression program
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Inmune Bio, Inc. Q1 FY2024 Earnings Call
Positive tone Alzheimer's Phase II AD02 trial enrollment and design Regulatory pathway and FDA interaction XPro long-term safety and patient experience
Revenue
$14,000
▼ 63.2% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Inmune Bio, Inc. Q4 FY2023 Earnings Call
Confident tone XPro Phase 2 Alzheimer's trial design and confidence INKmune prostate cancer trial Pipeline expansion beyond Alzheimer's
Revenue
$28,000*
▼ 71.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Inmune Bio, Inc. Q3 FY2023 Earnings Call
Revenue
$43,000
▼ 56.1% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Inmune Bio, Inc. Q2 FY2023 Earnings Call
Revenue
$46,000
▲ 187.5% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Inmune Bio, Inc. Q1 FY2023 Earnings Call
Revenue
$38,000
▼ 76.7% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-03
Inmune Bio, Inc. Q4 FY2022 Earnings Call
Revenue
$97,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Inmune Bio, Inc. Q3 FY2022 Earnings Call
Revenue
$98,000
▲ 600% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Inmune Bio, Inc. Q2 FY2022 Earnings Call
Revenue
$16,000
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Inmune Bio, Inc. Q1 FY2022 Earnings Call
Revenue
$163,000
▲ 3975% YoY
Diluted EPS
$-0.39
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-04
Inmune Bio, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Inmune Bio, Inc. Q3 FY2021 Earnings Call
Revenue
$14,000
Diluted EPS
$-0.55
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Inmune Bio, Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Inmune Bio, Inc. Q1 FY2021 Earnings Call
Revenue
$4,000
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-05
Inmune Bio, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Inmune Bio, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Inmune Bio, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Inmune Bio, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inmune Bio, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 78 filings 78 filers Visit website Investor relations